• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

术后无功能垂体腺瘤的自然病程:系统评价和荟萃分析。

Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis.

机构信息

Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China.

出版信息

Neuroendocrinology. 2012;96(4):333-42. doi: 10.1159/000339823. Epub 2012 Aug 28.

DOI:10.1159/000339823
PMID:22687984
Abstract

OBJECTIVE

Previous studies attempting to define the natural history of postoperative nonfunctioning pituitary adenomas (pNFPAs) were somewhat limited by selection bias and/or small numbers and/or lack of consistency among the study findings. The aim of this study was to scrutinize the literature in order to analyze the natural history of pNFPAs.

METHODS

Electronic database including MEDLINE, PubMed and Cochrane CENTRAL were searched. The literature relating to the patients with pNFPAs without postoperative radiotherapy and pharmacotherapy was collected. Eligible studies reported on the rate of tumor recurrence, the tumor growth-free survival rate (TGFSR) at 5 and 10 years, and/or the residual tumor volume doubling time (TVDT).

RESULTS

19 studies met the criteria. The pNFPAs were divided into two groups: the pooled recurrence rate of group I without detectable residual tumor (371 patients) was 12% (95% CI 6-19%), the TGFSR at 5 and 10 years were 96% (95% CI 89-99%) and 82% (95% CI 65-94%), respectively. The pooled recurrence rate of group II with residual tumor (600 patients) was 46% (95% CI 36-56%), the TGFSR at 5 and 10 years were 56% (95% CI 41-71%) and 40% (95% CI 27-53%), respectively. The mean TVDT was 3.4 years (95% CI 2.4-4.5 years).

CONCLUSIONS

pNFPAs, with or without detectable residual tumor, need stratification of treatment and radiological/endocrinological follow-up strategy. According to the TVDT, residual tumor regrowth is very slow, which permits an extensive and safe follow-up program for most patients.

摘要

目的

之前试图定义术后无功能垂体腺瘤(pNFPAs)自然史的研究受到选择偏倚和/或数量较少和/或研究结果缺乏一致性的限制。本研究的目的是仔细审查文献,以分析 pNFPAs 的自然史。

方法

检索电子数据库包括 MEDLINE、PubMed 和 Cochrane CENTRAL。收集了与未接受术后放疗和药物治疗的 pNFPAs 患者相关的文献。符合条件的研究报告了肿瘤复发率、5 年和 10 年肿瘤无进展生存率(TGFSR)和/或残留肿瘤体积倍增时间(TVDT)。

结果

19 项研究符合标准。将 pNFPAs 分为两组:无残留肿瘤的 I 组(371 例)的总复发率为 12%(95%CI 6-19%),5 年和 10 年 TGFSR 分别为 96%(95%CI 89-99%)和 82%(95%CI 65-94%)。有残留肿瘤的 II 组(600 例)的总复发率为 46%(95%CI 36-56%),5 年和 10 年 TGFSR 分别为 56%(95%CI 41-71%)和 40%(95%CI 27-53%)。平均 TVDT 为 3.4 年(95%CI 2.4-4.5 年)。

结论

有或无残留肿瘤的 pNFPAs 需要分层治疗和影像学/内分泌学随访策略。根据 TVDT,残留肿瘤的再生长非常缓慢,这允许为大多数患者制定广泛而安全的随访计划。

相似文献

1
Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis.术后无功能垂体腺瘤的自然病程:系统评价和荟萃分析。
Neuroendocrinology. 2012;96(4):333-42. doi: 10.1159/000339823. Epub 2012 Aug 28.
2
Electronic cigarettes for smoking cessation.电子烟戒烟。
Cochrane Database Syst Rev. 2021 Sep 14;9(9):CD010216. doi: 10.1002/14651858.CD010216.pub6.
3
Electronic cigarettes for smoking cessation.电子烟戒烟。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD010216. doi: 10.1002/14651858.CD010216.pub7.
4
Chemoprevention of colorectal cancer: systematic review and economic evaluation.结直肠癌的化学预防:系统评价和经济评估。
Health Technol Assess. 2010 Jun;14(32):1-206. doi: 10.3310/hta14320.
5
Electronic cigarettes for smoking cessation.电子烟戒烟。
Cochrane Database Syst Rev. 2024 Jan 8;1(1):CD010216. doi: 10.1002/14651858.CD010216.pub8.
6
Electronic cigarettes for smoking cessation.用于戒烟的电子烟。
Cochrane Database Syst Rev. 2025 Jan 29;1(1):CD010216. doi: 10.1002/14651858.CD010216.pub9.
7
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
8
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
10
Heated tobacco products for smoking cessation and reducing smoking prevalence.加热烟草制品戒烟和降低吸烟率。
Cochrane Database Syst Rev. 2022 Jan 6;1(1):CD013790. doi: 10.1002/14651858.CD013790.pub2.

引用本文的文献

1
"Tamoxifen for residual NF-PitNETs: A Proof-of-Concept study integrating receptor profiling, pilot trial, and target pathway analysis".他莫昔芬用于残留的神经内分泌垂体肿瘤:一项整合受体分析、试点试验和靶标通路分析的概念验证研究
Endocrine. 2025 Sep 1. doi: 10.1007/s12020-025-04404-7.
2
Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study.无功能垂体大腺瘤术后进展的预测因素:一项西班牙多中心研究
J Endocrinol Invest. 2025 Aug 8. doi: 10.1007/s40618-025-02674-6.
3
MRI based radiomics nomogram for predict recurrence of non functioning pituitary macroadenomas post surgery.
基于MRI的影像组学列线图预测无功能垂体大腺瘤术后复发情况
Sci Rep. 2025 Apr 14;15(1):12841. doi: 10.1038/s41598-025-89907-z.
4
Outcomes of transsphenoidal surgery for pituitary adenomas in Spain: a retrospective multicenter study.西班牙垂体腺瘤经蝶窦手术的结果:一项回顾性多中心研究。
Front Endocrinol (Lausanne). 2025 Feb 21;16:1529418. doi: 10.3389/fendo.2025.1529418. eCollection 2025.
5
Impact of insurance on outcomes of patients undergoing endoscopic transsphenoidal surgery for non-functional pituitary adenomas: a single institution study.保险对非功能性垂体腺瘤患者经蝶窦内镜手术结局的影响:一项单机构研究
Pituitary. 2024 Dec 30;28(1):14. doi: 10.1007/s11102-024-01478-w.
6
A Study in Pituitary Neuroendocrine Tumors (PitNETs): Real-Life Data Amid Baseline and Serial CT Scans.垂体神经内分泌肿瘤(PitNETs)研究:基线和系列CT扫描中的真实数据
Cancers (Basel). 2024 Oct 14;16(20):3477. doi: 10.3390/cancers16203477.
7
Stereotactic radiosurgery for recurrent/residual nonfunctioning pituitary adenoma: a single-arm systematic review and meta-analysis.立体定向放射外科治疗复发性/残留无功能垂体腺瘤:一项单臂系统评价和荟萃分析。
Acta Neurochir (Wien). 2024 Oct 2;166(1):392. doi: 10.1007/s00701-024-06296-4.
8
Risk factor analysis and prediction model to establish recurrence or progression of non-functioning pituitary adenomas in men after transnasal sphenoidal surgery.经鼻蝶窦手术后男性无功能垂体腺瘤复发或进展的危险因素分析及预测模型的建立。
Sci Rep. 2024 Sep 16;14(1):21607. doi: 10.1038/s41598-024-72944-5.
9
KLHL14 and E-Cadherin Nuclear Co-Expression as Predicting Factor of Nonfunctioning PitNET Invasiveness: Preliminary Study.KLHL14与E-钙黏蛋白核共表达作为无功能垂体神经内分泌肿瘤侵袭性的预测因素:初步研究
J Clin Med. 2024 Jul 28;13(15):4409. doi: 10.3390/jcm13154409.
10
Lanreotide versus placebo for tumour reduction in patients with a Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment.兰瑞肽对比安慰剂用于镓- DOTATATE PET阳性、临床无功能垂体大腺瘤患者肿瘤缩小的疗效观察(GALANT研究):一项随机、多中心、双盲结局评估的3期试验
Lancet Reg Health Eur. 2024 May 13;42:100923. doi: 10.1016/j.lanepe.2024.100923. eCollection 2024 Jul.